|Description||CAY10505 is a phosphatidylinositol 3-kinase-γ inhibitor, was found to significantly improve acetylcholine-induced endothelium dependent relaxation, serum nitrate and (or) nitrite level, glutathione level, and the vascular endothelial lining in hypertensive rats. CAY10505, may improve hypertension-associated vascular endothelial dysfunction. Inhibition of PI3Kγ might be a useful approach in the therapeutics of vascular endothelium dysfunction.|
|Synonyms||CAY10505; CAY 10505; CAY-10505|
MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.
Desmethyl-VS-5584, a demethyl analogue of VS-5584, is a PI3K/mTOR kinase inhibitor for the treatment of cancer.
NVP-BKM120 Hcl(BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively.
Inhibition of p110α alone by A66 treatment is sufficient to block insulin signalling to Akt/PKB in certain cell lines that harbor H1047R mutations in PIK3CA and...
AZD-8835 was selected as a clinical candidate for the treatment of PIK3CA-dependent cancers and is currently in phase I clinical trials. It is an orally bioavai...
Alpelisib, also known as BLY719, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor...
ON 146040 was highly potent in killing hematologic tumor cells with IC50 values in the 150 to 1,000 nM range. In biochemical testing, ON 146040 inhibited PI3K α...
Copanlisib hydrochloride is a potent inhibitor of Class I phosphoinositide 3-kinase which showed a therapeutic effect on non-Hodgkin lymphoma. It was approved t...
TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit. Recent studies showed that TGX-221 has antiproliferat...
GSK2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineopla...
PQR530 is a potent dual pan PI3K/mTOR inhibitor undergoing phase II clinical trials in 2016. Aberrant activation of the PI3K/mTOR signaling pathway promotes the...
GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asth...
TGR-1202 hydrochloride is the hydrochloride salt of TGR-1202.TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which i...
Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
SF2523 is a dual inhibitor of phosphatidylinositol 3-kinase and bromodomain-containing protein 4 with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for ...
PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR (Kis= 10.6 nM and 12.5 nM for mTOR and PI3Kα, respectively).
740 Y-P is a cell-permeable phosphopeptide activator of PI3K. It binds to the p85 N- and C-terminal SH2 domains of PI3K but not to GST or the N-terminal domain ...
In the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed ...